Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: A Spanish National Healthcare System perspective

  1. Driessen, M.T.
  2. Whalen, J.
  3. Seewoodharry Buguth, B.
  4. Vallejo-Aparicio, L.A.
  5. Naya, I.P.
  6. Asukai, Y.
  7. Alcázar-Navarrete, B.
  8. Miravitlles, M.
  9. García-Río, F.
  10. Risebrough, N.A.
Revue:
Respiratory Research

ISSN: 1465-993X,  1465-9921

Année de publication: 2018

Volumen: 19

Número: 1

Type: Article

DOI: 10.1186/S12931-018-0916-7 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus